Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following ...

Hello, and welcome to the Transgene First-Half 2023 Financial Results and Business Update Call. Please note this conference is being recorded and for the duration of the call your lines will be on ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock ...

Fundraising: EUR105 million raised in December 2025. Debt Conversion: EUR39 million debt converted into equity, making the company virtually debt-free. Cash Burn: Approximately EUR38.2 million in 2025 ...

Earnings call Transgene delivered robust clinical progress in 2025, highlighted by phase I data for TG4050 showing 100% disease-free survival in HPV-negative head and neck cancer and strong ...

Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) announced today a collaboration agreement for the creation of a new state-of-the-art industrial platform ...

Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial reporting dates for 2017: About Transgene Transgene S.A. (Euronext: TNG), ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.